Patents by Inventor Hironori Nakagami
Hironori Nakagami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230374103Abstract: Provided are preventive or therapeutic agents for fibrotic diseases and cancer. A Wnt signaling pathway inhibitor or a preventive and therapeutic agent for fibrotic diseases or cancer, both comprising an oligopeptide consisting of an amino acid sequence containing a DE loop sequence of RANKL protein and a ?-strand sequence of RANKL protein placed adjacent to the N-terminal side of the DE loop sequence.Type: ApplicationFiled: September 27, 2021Publication date: November 23, 2023Applicant: OSAKA UNIVERSITYInventors: Munehisa SHIMAMURA, Hironori NAKAGAMI, Ryuichi MORISHITA
-
Patent number: 11819537Abstract: The present invention provides a preventive or therapeutic method for an inflammatory skin disease, such as psoriasis, the method comprising administering an oligopeptide as an active ingredient. More specifically, the invention provides a preventive or therapeutic method for an inflammatory skin disease, the method comprising administering an oligopeptide consisting of an amino acid sequence containing a DE loop sequence of RANKL protein and a ?-strand D sequence of RANKL protein placed adjacent to the N-terminal side of the DE loop sequence.Type: GrantFiled: November 7, 2017Date of Patent: November 21, 2023Assignee: OSAKA UNIVERSITYInventors: Munehisa Shimamura, Hironori Nakagami, Yuka Ikeda, Ryuichi Morishita, Hiroshi Koriyama
-
Publication number: 20230330214Abstract: Provided is DNA that: encodes a coronavirus (SARS CoV-2) spike protein or a fragment thereof; and has been optimized to partially or fully exhibit a codon included in a DNA sequence.Type: ApplicationFiled: September 30, 2021Publication date: October 19, 2023Applicants: OSAKA UNIVERSITY, TAKARA BIO INC., ANGES, INC.Inventors: Hironori NAKAGAMI, Ryuichi MORISHITA, Hiroki HAYASHI, Yasunori AMAISHI, Sachiko OKAMOTO, Junichi MINENO, Hisato IKAI, Junko MICHIBATA, Takao KOMATSUNO
-
Publication number: 20230310561Abstract: The present invention provides an immunogenic composition comprising an antigenic peptide and a carrier protein, wherein the antigenic peptide is capable of eliciting production of an antibody against a phosphorylated tau protein and is a human tau protein fragment containing (1) YSpSPGpSPG (SEQ ID NO: 2), (2) AKpSpTPpTAE (SEQ ID NO: 5), (3) AKpSpTPTAE (SEQ ID NO: 31), (4) AKpSTPpTAE (SEQ ID NO: 32), (5) AKSpTPpTAE (SEQ ID NO: 33), or (6) IVpYKpSPV (SEQ ID NO: 24).Type: ApplicationFiled: September 7, 2021Publication date: October 5, 2023Applicant: OSAKA UNIVERSITYInventors: Hironori NAKAGAMI, Ryuichi MORISHITA, Shuko TAKEDA, Hiroki HAYASHI
-
Patent number: 11712466Abstract: The present invention provides a vaccine composition for treating or preventing cancer expressing VASH2, containing a peptide including an amino acid sequence represented by SEQ ID NO: 4.Type: GrantFiled: August 30, 2018Date of Patent: August 1, 2023Assignee: TOHOKU UNIVERSITYInventors: Yasufumi Sato, Hironori Nakagami, Hideki Tomioka
-
Publication number: 20220267374Abstract: An immunity inducer contains, as an active ingredient, any of a peptide (a) or (b) below, or an expression vector having a structural gene including a region encoding the peptide. (a) A peptide including an amino acid sequence represented by SEQ ID NO: 1 or 2; (b) a peptide having immunity induction activity and including an amino acid sequence in which one or several amino acids are deleted, substituted or added in the amino acid sequence represented by SEQ ID NO: 1 or 2. A pharmaceutical composition for preventing or treating aging-related diseases includes the immunity inducer and an adjuvant.Type: ApplicationFiled: July 7, 2020Publication date: August 25, 2022Applicant: Juntendo Educational FoundationInventors: Tohru MINAMINO, Hironori NAKAGAMI
-
Patent number: 11421025Abstract: The present invention provides a vaccine against IL-17A, which uses, as an immunogen, a polypeptide containing the amino acid sequence shown in SEQ ID NO: 1, or an amino acid sequence derived from a non-human mammal, which corresponds to SEQ ID NO: 1, a prophylactic or therapeutic agent containing the vaccine for diseases involving IL-17A as an aggravation factor, and the like.Type: GrantFiled: December 26, 2014Date of Patent: August 23, 2022Assignee: OSAKA UNIVERSITYInventors: Hiroshi Koriyama, Hironori Nakagami, Ryuichi Morishita
-
Publication number: 20220088141Abstract: Described herein is the discovery that HGFs activate the growth and migration of lymphatic endothelial cells and thereby promote lymphangiogenesis. The present invention is based on this finding, and provides lymphangiogenesis-promoting agents comprising as active ingredients HGFs, or proteins or compounds functionally equivalent thereto. Based on the finding described above, the present invention also provides methods for promoting lymphangiogenesis which comprise the step of locally administering HGFs or proteins functionally equivalent thereto to affected areas in patients with lymphedema.Type: ApplicationFiled: April 26, 2021Publication date: March 24, 2022Applicant: AnGes, Inc.Inventors: Ryuichi Morishita, Yasufumi Kaneda, Hironori Nakagami, Yukihiro Saito
-
Publication number: 20210205446Abstract: The present invention provides a vaccine containing a complex of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and an epitope of a disease-causing biological protein such as DPP4, IL-17A, IgE, S100A9 or PCSK9, which vaccine uses a less antigenic carrier protein and is capable of inducing antibody production to serve as an effective vaccine.Type: ApplicationFiled: March 12, 2021Publication date: July 8, 2021Applicants: OSAKA UNIVERSITY, FUNPEP CO., LTD.Inventors: Hironori NAKAGAMI, Ryuichi MORISHITA, Akiko TENMA
-
Patent number: 11020464Abstract: Provided is an immunogenic composition comprising an antigenic peptide capable of inducing production of a neutralizing antibody against S100A9 and a carrier protein. The immunogenic composition can be used as a highly safe antithrombotic vaccine having antithrombotic effect without a long-term bleeding risk and is useful for the prevention of a disease associated with thrombus formation in which platelet aggregation is involved, particularly for the prevention of recurrent ischemic stroke.Type: GrantFiled: February 20, 2018Date of Patent: June 1, 2021Assignees: OSAKA UNIVERSITY, FUNPEP CO., LTD.Inventors: Munehisa Shimamura, Tomohiro Kawano, Hironori Nakagami, Ryuichi Morishita, Hideki Mochizuki, Akiko Tenma, Takako Ehara
-
Patent number: 10980876Abstract: The present invention provides a vaccine containing a complex of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and an epitope of a disease-causing biological protein such as DPP4, IL-17A, IgE, S100A9 or PCSK9, which vaccine uses a less antigenic carrier protein and is capable of inducing antibody production to serve as an effective vaccine.Type: GrantFiled: March 24, 2017Date of Patent: April 20, 2021Assignees: OSAKA UNIVERSITY, FUNPEP CO., LTD.Inventors: Hironori Nakagami, Ryuichi Morishita, Akiko Tenma
-
Publication number: 20200282033Abstract: The present invention provides a vaccine composition for treating or preventing cancer expressing VASH2, containing a peptide including an amino acid sequence represented by SEQ ID NO: 4.Type: ApplicationFiled: August 30, 2018Publication date: September 10, 2020Applicant: TOHOKU UNIVERSITYInventors: Yasufumi SATO, Hironori NAKAGAMI, Hideki TOMIOKA
-
Patent number: 10695420Abstract: The present invention provides a combination preparation for inducing a specific immune response to an antigenic peptide, which contains (I) the antigenic peptide, and (II) an expression vector encoding a chimeric hepatitis B virus core antigen polypeptide, into which the antigenic peptide has been inserted or added, wherein said antigenic peptide is inserted in a region of amino acid residues 74-87 or 130-138 of the hepatitis B virus core antigen polypeptide, or added to the N-terminal or C-terminal of the hepatitis B virus core antigen polypeptide, wherein the antigenic peptide of (I) and the expression vector of (II) are substantially simultaneously administered to a subject.Type: GrantFiled: November 20, 2015Date of Patent: June 30, 2020Assignees: ANGES, INC., OSAKA UNIVERSITY, DS PHARMA ANIMAL HEALTH CO., LTD.Inventors: Hironori Nakagami, Ryuichi Morishita, Hiroshi Koriyama, Hideki Tomioka, Kenji Naohara
-
Patent number: 10543261Abstract: The present invention provides a therapeutic or prophylactic agent for cancer, containing an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of VEGF and/or a specific epitope of angiopoietin-2, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.Type: GrantFiled: August 28, 2013Date of Patent: January 28, 2020Assignees: Osaka University, AnGes, Inc.Inventors: Hironori Nakagami, Mariko Kyutoku, Ryuichi Morishita, Hideki Tomioka
-
Publication number: 20200023045Abstract: Provided is an immunogenic composition comprising an antigenic peptide capable of inducing production of a neutralizing antibody against S100A9 and a carrier protein. The immunogenic composition can be used as a highly safe antithrombotic vaccine having antithrombotic effect without a long-term bleeding risk and is useful for the prevention of a disease associated with thrombus formation in which platelet aggregation is involved, particularly for the prevention of recurrent ischemic stroke.Type: ApplicationFiled: February 20, 2018Publication date: January 23, 2020Applicants: OSAKA UNIVERSITY, FUNPEP CO., LTD.Inventors: Munehisa SHIMAMURA, Tomohiro KAWANO, Hironori NAKAGAMI, Ryuichi MORISHITA, Hideki MOCHIZUKI, Akiko TENMA, Takako EHARA
-
Patent number: 10517926Abstract: Provided is an oligopeptide having preventive and therapeutic effects on infarction diseases. The oligopeptide contains a DE loop sequence of RANKL protein, and has inhibitory activity on proinflammatory cytokine secretion from cells.Type: GrantFiled: May 16, 2016Date of Patent: December 31, 2019Assignee: Osaka UniversityInventors: Munehisa Shimamura, Hironori Nakagami, Hitomi Kurinami, Ryuichi Morishita
-
Publication number: 20190365859Abstract: The present invention provides a preventive or therapeutic agent for an inflammatory skin disease, such as psoriasis, the agent comprising an oligopeptide as an active ingredient. More specifically, the invention provides a preventive or therapeutic agent for an inflammatory skin disease, the agent comprising an oligopeptide consisting of an amino acid sequence containing a DE loop sequence of RANKL protein and a ?-strand D sequence of RANKL protein placed adjacent to the N-terminal side of the DE loop sequence.Type: ApplicationFiled: November 7, 2017Publication date: December 5, 2019Inventors: Munehisa Shimamura, Hironori Nakagami, Yuka Ikeda, Ryuichi Morishita, Hiroshi Koriyama
-
Patent number: 10463592Abstract: An object of the present invention to discover a short peptide having an anti-aging effect and to provide a novel anti-aging agent comprising the peptide as an active ingredient. The inventors have discovered that a peptide consisting of an amino acid sequence ELKLIFLHRLKRLRKRLKRK (SEQ ID NO: 1) or a partial sequence thereof and having one or more effects selected from the group consisting of promoting fibroblast growth, promoting hyaluronic acid production and contracting a collagen gel, or a derivative or salt of the peptide is useful as an active ingredient of an anti-aging agent.Type: GrantFiled: December 7, 2017Date of Patent: November 5, 2019Assignee: Osaka UniversityInventors: Hironori Nakagami, Ryuichi Morishita, Hideki Tomioka, Akiko Tenma
-
Publication number: 20190321444Abstract: Described herein is the discovery that HGFs activate the growth and migration of lymphatic endothelial cells and thereby promote lymphangiogenesis. The present invention is based on this finding, and provides lymphangiogenesis-promoting agents comprising as active ingredients HGFs, or proteins or compounds functionally equivalent thereto. Based on the finding described above, the present invention also provides methods for promoting lymphangiogenesis which comprise the step of locally administering HGFs or proteins functionally equivalent thereto to affected areas in patients with lymphedema.Type: ApplicationFiled: January 3, 2019Publication date: October 24, 2019Applicant: AnGes, Inc.Inventors: RYUICHI MORISHITA, Yasufumi Kaneda, Hironori Nakagami, Yukihiro Saito
-
Publication number: 20190105388Abstract: The present invention provides a vaccine containing a complex of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and an epitope of a disease-causing biological protein such as DPP4, IL-17A, IgE, S100A9 or PCSK9, which vaccine uses a less antigenic carrier protein and is capable of inducing antibody production to serve as an effective vaccine.Type: ApplicationFiled: March 24, 2017Publication date: April 11, 2019Applicants: OSAKA UNIVERSITY, FUNPEP CO., LTD.Inventors: Hironori NAKAGAMI, Ryuichi MORISHITA, Akiko TENMA